The People of Tulane Cancer Center Research

Aaron HoffmanAaron Hoffman, PhD
Assistant Professor, Epidemiology
Tulane Cancer Center Program Member

Contact Information
Phone: 504-988-1560
Address: 1430 Tulane Ave., SL-68, New Orleans, LA 70112

Biographical Narrative

Aaron E. Hoffman earned his doctorate in epidemiology from Yale University in 2009, followed by an additional year of postdoctoral training. His research focuses on the molecular epidemiology of cancer, with a particular interest in the influence of genetic and epigenetic mechanisms of circadian disruption on cancer susceptibility. He is also interested in more broad analyses of the inter-individual variability in gene expression, and the extent to which epigenetic mechanisms such as post-transcriptional gene regulation by small non-coding RNA species and other non-traditional regulatory instruments (e.g. alternative polyadenylation), influence cancer-relevant processes and contribute to the complex risk structure which is observable at the population level. In each case, the goal of his research is to generate insights with translational implications which may be useful for the treatment and prevention of cancer.

Selected Publications
Hoffman AE, Yi C, Zheng T, Stevens RG, Zhang Y, Leaderer D, Holford T, Zhu Y (2010) CLOCK in Breast Tumorigenesis: Genetic, Epigenetic, and Transcriptional Profiling Analyses. Cancer Res 70(4):1459-68 *

Hoffman AE, Zheng T, Yi C, Stevens RG, Ba Y, Zhang Y, Leaderer D, Holford T, Hansen J, Zhu Y (2010) The core circadian gene cryptochrome 2 influences breast cancer risk, possibly by mediating hormone signaling . Cancer Prev Res 3(4):539-48

Hoffman AE, Zheng T, Yi C, Stevens RG, Ba Y, Zhang Y, Leaderer D, Holford T, Zhu Y (2010) Phenotypic effects of the circadian gene cryptochrome 2 on cancer-related pathways. BMC Cancer 10(1):110

Zhu Y, Stevens RG, Hoffman AE, FitzGerald L, Kwon EM, Ostrander EA, Davis S, Zheng T, Stanford JL (2009) Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. Cancer Res 69(24):9315-22

Hoffman AE, Zheng T, Yi C, Weidhaas J, Slack F, Zhang Y, Paranjape T, Leaderer D, Zhu Y (2009) miR-196a-2 in breast tumorigenesis: evidence from a genetic and epigenetic association study and functional analysis. Cancer Res 69(14):5970-7 *

Hoffman AE , Zheng T, Stevens RG, Ba Y, Zhang Y, Leaderer D, Yi C, Holford T, Zhu Y (2009) Clock-cancer connection in non-Hodgkin's lymphoma: a genetic association study and pathway analysis of the circadian gene Cryptochrome 2. Cancer Res 69(8):3605-13 *

Yi C, Zheng T, Leaderer D, Hoffman A, Zhu Y (2009) Cancer-related transcriptional targets of the circadian gene NPAS2 identified by genome-wide ChIP-on-chip analysis. Cancer Lett. 284(2):149-56

Yi C, Mu L, Rigault de la Longrais IA, Sochirca O, Arisio R, Yu H, Hoffman AE, Zhu Y, Katsaro D (2009) The circadian gene NPAS2 is a novel prognostic biomarker for breast cancer. Breast Cancer Res Treat 120(3):663-9

Hoffman AE, Zheng T, Ba Y, Zhu Y (2008) The circadian gene NPAS2, a putative tumor suppressor, is involved in DNA damage response. Mol Cancer Res 6:1461-1468

Zhu Y, Hoffman A, Wu X, Zhang H, Zhang Y, Leaderer D, Zheng T (2008) Correlating observed odds ratios from lung cancer case-control studies to SNP functional scores predicted by bioinformatic tools. Mutat Res 639:80-88

* Three most representative publications


1430 Tulane Ave, New Orleans, LA 70112